Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
A single center pilot study to determine the protective effects of RhuMAB-E25 on airway
physiology and biology in allergic asthmatics that undergo bronchoprovocation with
methacholine.
The primary study objective determines the protective impact of RhuMAB-E25 on airway
inflammation as reflected in exhaled nitric oxide (NO) levels in allergic asthmatics.
The secondary objective determines the protective effect of rhuMAB E25 against airway
bronchoconstriction as reflected in the Provocative Concentration of methacholine to cause a
20% fall in FEV1(PC20) with methacholine challenge testing.